Capital Flow Monitor · Sponsors · CIK 2020048
Averna Therapeutics Inc.
134 COOLIDGE AVENUE, WATERTOWN, MA, 10022 · 972 73 2822600
Other Health Care · Corporation· inc. DELAWARE true 2022
Fit score
—
Offering
$85.0M
Sold
$85.0M
% sold
100.0%
Investors
13
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-03-20 | D/A ·current | 506(b) | $85.0M | $85.0M | 100.0% | 13 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- Thomas Barnes — Director / Executive Officer, Watertown, MA
- Richard Morris — Executive Officer, Watertown, MA
- Tal Zaks — Director / Executive Officer, Watertown, MA
- Roy Amariglio — Director, Watertown, MA
-
Stephen Squinto — Director, Watertown, MA
5 other raises
- 270 Healthcare Growth Fund I LP $113.9M of —
- 270 Healthcare Growth Fund I (LUX) SCSp-RAIF $113.9M of —
- 270 Life Sciences Private Capital Fund II (US) LP $0 of —
- 270 Life Sciences Private Capital Fund II (Cayman) LP $0 of —
- Enlaza Therapeutics, Inc. $15.0M of $15.0M · 100.0%
- Raju Prasad — Director, Watertown, MA
- Michal Silverberg — Director, Watertown, MA
-
Nick Olsen — Director, Watertown, MA
1 other raise
- Character Biosciences, Inc. $8.9M of $19.6M · 45.1%
-
Henry Chen — Director, Watertown, MA
1 other raise
- Instylla, Inc. $34.8M of $35.0M · 99.3%
- Dylan Morris — Director, Watertown, MA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.